ArriVent expects topline data from lung cancer drug trial in early 2026

ArriVent BioPharma (AVBP) announced that topline data from its pivotal Phase 3 FURVENT study of firmonertinib for first-line EGFR exon20 insertion mutant non-small cell lung cancer (NSCLC) is expected in early 2026, following trial enrollment completion in Q1 2025. The company, which recently completed a $75 million public offering to fund development, holds FDA Breakthrough Therapy Designation for firmonertinib and has received strong buy ratings from analysts, including Goldman Sachs, citing high probability of clinical efficacy. This development, coupled with positive Phase 1b data showing a 16-month median progression-free survival and significant CNS activity, highlights the advancement of a key oncology asset targeting an unmet medical need.

Analysis

ArriVent BioPharma (AVBP) has established a clear timeline for its key value-driving catalyst, with topline data from the pivotal Phase 3 FURVENT study of firmonertinib expected in early 2026. The trial, which completed enrollment of 398 patients in Q1 2025, evaluates the drug against the current standard-of-care chemotherapy in first-line non-small cell lung cancer (NSCLC) with EGFR exon20 insertion mutations, a population representing approximately 9% of all EGFR mutations. The asset is significantly de-risked by its prior approval and use in China for related indications, and it holds both FDA Breakthrough Therapy and Orphan Drug Designations, signaling regulatory support. Confidence in the drug's mechanism is further supported by recent Phase 1b data in a different mutation type (EGFR PACC), which demonstrated a 16-month median progression-free survival and significant central nervous system activity. Financially, the company has shored up its balance sheet with a recent $75 million public offering to fund development through these key milestones. This strategic and clinical progress is reflected in a strong buy consensus from Wall Street, with analysts like Goldman Sachs resuming coverage with a Buy rating and price targets ranging from $33 to $45, citing a high probability of competitive clinical efficacy.

Key Decisions for Investors

• The primary value inflection point for ArriVent BioPharma is the topline Phase 3 FURVENT data expected in early 2026, positioning the stock as a long-term, catalyst-driven holding.
• Investors should monitor for any interim data from the company's other ongoing trials, such as the study in EGFR PACC mutations, which could serve as important de-risking events ahead of the main readout.
• While the recent $75 million offering extends the cash runway towards the catalyst, the competitive landscape and inherent clinical trial execution risks remain key factors to watch, especially given the mention of a competitor's drug approval.